Meeting
2023 ASCO Annual Meeting
Product characteristics and clinical trial design for T-Plex: Multiplexed, enhanced T cell receptor engineered T cell therapy for solid tumors.
Authors
Shrikanta Chattopadhyay
TScan Therapeutics, Waltham, MA
Shrikanta Chattopadhyay , Antoine Boudot , Ribhu Nayar , Hannah Bader , Nancy Nabilsi , Jenny Tadros , Badr Kiaf , Yifan Wang , Amanda Kordosky , Chris Malcuit , Yun Wang , Marlyane Motta , Nina Abelowitz , Ray Lockard , Cagan Gurer , Debora Barton , Gavin MacBeath
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2554)
DOI
10.1200/JCO.2023.41.16_suppl.2554
Abstract #
2554
Poster Bd #
396
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared KRAS and TP53 mutations expressed by solid tumors in first-in-human phase 1 study.
First Author: Maria Pia Morelli
Poster
2022 ASCO Annual Meeting
![ZENYTH-ESO: Master protocol to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and myxoid/round cell liposarcoma [Substudy 3, GSK4427296].](https://d201v5jt9ylckg.cloudfront.net/288/14355/213211/213211_A1227_poster_pv.jpg)
ZENYTH-ESO: Master protocol to assess the safety and recommended phase II dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and myxoid/round cell liposarcoma [Substudy 3, GSK4427296].
First Author: Dejka M. Araujo
Poster
2020 ASCO Virtual Scientific Program
A phase I/II first-in-human study of a novel anti-MAGE-A4 TCR/anti-CD3 bispecific (IMC-C103C) as monotherapy and in combination with atezolizumab in HLA-A*02:01-positive patients with MAGE-A4-positive advanced solid tumors (IMC-C103C-101).
First Author: George R. Blumenschein, Jr.
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Phase I trial evaluating genetically modified autologous T cells (ACTengine IMA201) expressing a T-cell receptor recognizing a cancer/germline antigen in patients with squamous NSCLC or HNSCC.
First Author: George R. Blumenschein